Carcinoma News and Research RSS Feed - Carcinoma News and Research

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Researchers at UC Davis have shown that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces renal cell carcinoma invasiveness, growth rate, and blood vessel growth when combined with the anti-cancer therapy regorafenib. The study was published in the journal Molecular Cancer Therapeutics. [More]
HBcrAg may predict HCC development

HBcrAg may predict HCC development

Research suggests a role for hepatitis B core-related antigen in the prediction of hepatocellular carcinoma development in nucleos(t)ide analogue treatment-naïve patients with chronic hepatitis B virus infection. [More]
WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Japanese researchers have found that serum levels of glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein are a useful marker of not only the degree of liver fibrosis, but also progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. [More]
Endocrine Society urges physicians to increase screening for primary aldosteronism

Endocrine Society urges physicians to increase screening for primary aldosteronism

The Endocrine Society today issued a Clinical Practice Guideline calling on physicians to ramp up screening for primary aldosteronism, a common cause of high blood pressure. [More]
Drugs that block NOTCH signaling in many cancers could be effective against ACC

Drugs that block NOTCH signaling in many cancers could be effective against ACC

Using a novel cell culture approach, Yale Cancer Center researchers have discovered critical vulnerabilities in adenoid cystic carcinoma (ACC), a rare and lethal glandular cancer with a high recurrence rate and few treatment options. [More]
Scientists aim to identify marker that could indicate aggressive basal cell skin cancer

Scientists aim to identify marker that could indicate aggressive basal cell skin cancer

Most basal cell skin cancers are easily removed -- those on the arm, leg or back. But when the cancer is on the eyelid or when it starts to invade surrounding tissue, it's no longer straightforward. [More]
PerkinElmer’s Phenoptics solution has potential to predict biomarker for anti-PD1 therapies for Merkel cell carcinoma

PerkinElmer’s Phenoptics solution has potential to predict biomarker for anti-PD1 therapies for Merkel cell carcinoma

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that its Phenoptics™ quantitative pathology research system was an important component in skin cancer research published online in the April 19 edition of the New England Journal of Medicine. [More]
Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

In a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy. [More]
Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy. [More]
Experts discuss recent controversies related to breast cancer screening recommendations

Experts discuss recent controversies related to breast cancer screening recommendations

In 2015, American Cancer Society caused a stir in the oncology community—and among women in general—with the updated recommendation that women of average risk for breast cancer should commence annual mammography at age 45. [More]
Delay in radiation therapy increases chances of DCIS recurrence in women

Delay in radiation therapy increases chances of DCIS recurrence in women

Delaying radiation therapy too long after surgery significantly increases the risk of recurrent tumors in women treated for very early, or what is referred to as "stage 0," breast cancer, according to new research at Washington University School of Medicine in St. Louis. [More]
First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab. [More]
International panel reclassifies a type of thyroid tumor to reduce cancer overdiagnosis

International panel reclassifies a type of thyroid tumor to reduce cancer overdiagnosis

Led by researchers at the University of Pittsburgh School of Medicine, an international panel of pathologists and clinicians has reclassified a type of thyroid cancer to reflect that it is noninvasive and has a low risk of recurrence. The name change, described today in JAMA Oncology, is expected to reduce the psychological and medical consequences of a cancer diagnosis, potentially affecting thousands of people worldwide. [More]
HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness. [More]

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic lymphoma kinase (ALK) and have already received another treatment. In November 2015, the approval was extended to first-line treatment. [More]
New CWRU study identifies three glycosyltransferases as major mutational targets in colorectal cancer

New CWRU study identifies three glycosyltransferases as major mutational targets in colorectal cancer

Little is known about the molecular basis of aberrant protein glycosylation, a complex enzymatic process that is a hallmark of many human cancers including colorectal cancers (CRC), and how it may contribute to tumor progression. In a new study published in Scientific Reports, an online journal of the Nature Publishing Group, scientists at Case Western Reserve University School of Medicine have successfully characterized the mutational landscapes of glycosylation-associated genes in colon cancer, identifying three glycosyltransferases as significant mutational targets in CRC. [More]
Study identifies genetic differences in kidney tumors of African-Americans

Study identifies genetic differences in kidney tumors of African-Americans

A University of North Carolina Lineberger Comprehensive Cancer Center-led study has identified genetic differences in tumors of African-Americans with the most common type of kidney cancer compared with whites. [More]
SGO acting on ovarian cancer report recommendations

SGO acting on ovarian cancer report recommendations

During the Society of Gynecologic Oncology’s 47th Annual Meeting on Women’s Cancer today, SGO convened a panel of ovarian cancer experts to discuss the recently released report by the National Academy of Medicine (NAM), [More]
DAA medication could lead to revolution in hepatitis C treatment

DAA medication could lead to revolution in hepatitis C treatment

The cost of treating hepatitis C virus (HCV) could be cut up to 50 percent if mathematical models are used to predict when patients can safely stop taking direct-acting antiviral (DAA) medication, according to a new study by researchers at Loyola University Health System and Loyola University Chicago [More]
Mutated gene GT198 has strong potential in early diagnosis of breast cancer

Mutated gene GT198 has strong potential in early diagnosis of breast cancer

When mutated, a gene known for its ability to repair DNA, appears to instead cause breast cancer, scientists report. [More]
Advertisement